Free tools Windows power users keep installed
One-click scans. No signup required.
Theranos blood tests were not a proven, broadly accurate replacement for conventional laboratory testing. The company promoted a proprietary analyzer that supposedly could run a wide range of tests from a finger-stick sample, with faster, cheaper and more accurate results. Federal records and trial evidence instead describe a system with limited capability, unreliable results for several important analytes, and repeated use of conventional machines for tests that customers were led to believe came from Theranos technology.
That history does not establish that every capillary (finger-stick) test is inaccurate. The meaningful comparison is assay by assay: what specimen was collected, which analyzer performed the measurement, how the method was calibrated and controlled, and whether an unexpected result was confirmed.
What Theranos promised patients and doctors
Theranos marketed a small-volume blood collection system built around a proprietary analyzer. A patient would provide a finger-stick sample rather than a conventional venous draw, and the company said that this tiny sample could support a comprehensive menu of tests. The advertised benefits were convenience, speed, lower cost and accuracy that would match or exceed established laboratories.
The promise mattered because blood results influence diagnoses, medication changes, pregnancy decisions and referrals for further care. A result that is wrong in a clinically important direction is not merely an inconvenience; it can trigger treatment or delay treatment. For that reason, a new testing system must demonstrate analytical performance and operate under laboratory quality requirements before patients can safely rely on it.
Quick wins for a faster PC:
Clear out junk files and repair common Windows errorsFree Scan →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →#1 Best Overall
Government records describe a materially narrower reality. The government’s case summary said the Theranos analyzer performed only a limited number of tests, had accuracy and reliability problems, was slower than competing devices and could not compete with established machines. The same account said the company repeatedly used conventional machines to obtain results that the public was led to believe came from the Theranos analyzer.
What the evidence says about accuracy
Analytes identified in the federal charging record
The 2018 federal charging record alleged that Elizabeth Holmes and Ramesh Balwani knew the system could not consistently produce accurate and reliable results for several named tests:
- Calcium
- Chloride
- Potassium
- Bicarbonate
- HIV testing
- Hemoglobin A1c (HbA1c)
- Human chorionic gonadotropin (hCG), used in pregnancy testing
- Sodium
These are not interchangeable measurements. Electrolytes such as sodium, potassium, chloride and bicarbonate can affect urgent clinical decisions; HbA1c is used to assess longer-term blood-glucose control; HIV and pregnancy tests have consequences that extend well beyond a laboratory report. The allegation was not that every result was wrong, but that the system could not reliably produce accurate results across the represented menu.
Examples presented in the government’s case
The Department of Justice and FDA sentencing account described a physician who repeatedly received extremely elevated prostate-specific antigen (PSA) values from Theranos. Traditional FDA-approved methods later showed those values were inaccurate. A persistently high PSA can lead to additional investigations and anxiety, so the discrepancy had practical clinical implications.
The Tool Desk
Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →The same account described pregnant patients whose Theranos hCG results suggested miscarriage even though confirmatory conventional tests indicated viable pregnancies. It also described an employee whose Theranos anticoagulation-related results led to an unnecessary medication adjustment; conventional testing subsequently showed normal levels. These examples illustrate why a numerical result cannot be judged only by whether a device prints it quickly. The result has to agree with validated performance and with the patient’s clinical picture.
What “inaccurate” means in this context
Laboratory quality has more than one dimension. Accuracy is how close a measurement is to the correct value. Precision is how consistently the method repeats a measurement under the same conditions. A method can be precise but inaccurate if it repeatedly gives the wrong value. A method can also be accurate on average but too variable for a particular clinical decision.
The federal allegations concern the ability to produce accurate and reliable results consistently. They do not justify a claim that every Theranos result was false, nor do they prove that every capillary assay in medicine is defective. The defensible conclusion is narrower and more important: patients and clinicians could not assume that the advertised Theranos menu had the validated performance of established laboratory methods.
How a conventional laboratory test differs
“Conventional” testing is not one machine or one company. It is a workflow used by hospital laboratories, independent laboratories and other certified facilities. The comparison below identifies the dimensions that matter when a new finger-stick system is evaluated against established testing.
Do these 3 things before closing this tab:
1Clear out junk files and repair common Windows errors2Fix the driver behind crashes, sound loss and screen glitches3Repair Windows errors before they cause bigger problems| Comparison point | Theranos representation and documented issue | Typical conventional-laboratory approach |
|---|---|---|
| Specimen | Finger-stick (capillary) blood and very small sample volumes were central to the marketing. Federal evidence described cases in which the resulting measurements were unreliable. | Many routine tests use venous blood collected into tubes, although validated capillary methods exist for particular assays and settings. |
| Test menu | Public claims suggested broad, comprehensive testing from one small sample. Government records said the proprietary analyzer could perform only a limited number of tests. | Established laboratories use multiple validated analyzers and methods, allowing a broad menu while specifying which specimen and method each assay requires. |
| Analyzer provenance | The company represented results as coming from its own technology, while the SEC complaint said the miniLab was never used for patient testing in its clinical laboratory and that traditional or third-party laboratories performed some testing. | The laboratory identifies the analyzer and method used, maintains records for that system and applies the method’s operating instructions. |
| Calibration and quality control | Accuracy and reliability problems were described in federal case materials; the public could not rely on the marketing claims as proof of validated performance. | Laboratories run calibration and quality-control procedures, investigate failures and document whether a test run can be released. |
| Turnaround time | Speed was a major selling point, yet the government’s case summary said the analyzer was slower than competing devices. | Turnaround varies by assay and facility. High-volume analyzers can process many specimens rapidly, but collection, transport, accessioning and review also affect the final time. |
| Confirmation when a result conflicts | Patients and clinicians described results that conflicted with conventional testing or clinical circumstances. | A clinician can repeat the assay, use a different validated method or send a specimen to another laboratory when a result is unexpected. |
| Oversight | Theranos was subject to laboratory and diagnostic-device oversight, and federal enforcement actions followed allegations of misleading representations and unreliable testing. | U.S. laboratories performing testing on people operate under CLIA requirements and may also use devices cleared or approved through FDA processes, depending on the test and its intended use. |
Finger-stick blood is not automatically inferior to venous blood
Capillary blood can be appropriate for some tests when the collection method, sample handling and assay have been validated for that specimen type. The problem in the Theranos case was the combination of sweeping claims, a small and limited analyzer capability, and documented reliability failures—not the mere fact that blood came from a finger.
A peer-reviewed study published in 2016 directly compared Theranos capillary testing with venous testing. It enrolled 60 healthy adults and used conventional venipuncture testing at Quest Diagnostics and LabCorp as the comparison workflow. That design is useful because it examines specimen type and laboratory process side by side. It does not support a universal conclusion that every capillary assay fails, that every venous assay is perfect, or that findings in healthy volunteers apply unchanged to people who are ill, taking medication or being tested for a different analyte.
Several practical differences can affect capillary results:
- Collection technique: squeezing a finger, inadequate warming or contamination can alter the sample.
- Sample volume: a very small specimen leaves less material for repeats, dilutions or additional testing when a result is outside the instrument’s measuring range.
- Matrix and concentration: capillary and venous blood are not identical specimens, and an assay must be validated for the type being used.
- Transport and timing: delays, temperature and tube handling can change some measurements before analysis.
- Patient condition: dehydration, poor circulation or severe illness can make collection more difficult and can affect interpretation.
A credible comparison therefore asks, “Was this particular assay validated on this particular specimen under this laboratory’s conditions?” It does not ask whether finger sticks are good or bad in the abstract.
Who regulated Theranos testing?
CMS and CLIA laboratory oversight
The Centers for Medicare & Medicaid Services (CMS) administers the Clinical Laboratory Improvement Amendments of 1988 (CLIA). CLIA establishes requirements intended to ensure that testing on human specimens is accurate, reliable and timely. Requirements cover laboratory operations, personnel, quality systems, proficiency testing and other controls appropriate to the testing performed.
CLIA oversight is different from deciding whether a particular diagnostic device works as claimed. A laboratory can have a certificate and still need to demonstrate that each method it uses is properly validated and controlled. Conversely, a device’s regulatory status does not by itself tell a patient whether a specific result is correct in a particular clinical situation.
FDA expertise over tests and medical devices
The FDA has the relevant federal role in evaluating medical devices and diagnostic tests, including whether a product is authorized or cleared for its intended use. A joint FDA-and-CMS statement distinguishes CMS responsibility for laboratory quality from FDA expertise concerning whether diagnostic tests work. In practice, a testing service can involve both questions: whether the laboratory meets CLIA standards and whether the device or assay is appropriate and authorized for the claimed use.
SEC and criminal enforcement
The Securities and Exchange Commission alleged in 2018 that Theranos, Holmes and Balwani raised more than $700 million from investors through misleading statements, including claims that a portable analyzer could perform comprehensive testing from finger-stick blood. The Department of Justice charging record alleged that advertising encouraged doctors and patients to purchase tests even though the company allegedly knew the system could not consistently produce accurate and reliable results.
The SEC complaint also stated that Theranos never used its miniLab for patient testing in its clinical laboratory and instead used traditional laboratories or third-party laboratories for some testing. That allegation is central to the difference between the public story and the operational reality: a result may have been generated by a conventional analyzer even while the service was marketed as proof that the proprietary system worked.
Balwani was ultimately sentenced to 155 months—12 years and 11 months—in the federal case, according to the 2022 Department of Justice/FDA account. The enforcement history does not turn every Theranos result into a known error, but it confirms that the representations and testing practices were treated as serious matters involving patient safety and investor deception.
Why a wrong result can harm a patient
Laboratory data are interpreted in context. A single unexpected value may lead to a repeat blood draw, medication change, imaging, referral or a decision to reassure a patient. When a result suggests a miscarriage, a dangerous electrolyte abnormality, an infection or a need for anticoagulation adjustment, an inaccurate number can alter the path of care before anyone recognizes the problem.
The cases described in federal records show three different pathways to harm:
Crashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minutePC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11- False elevation: repeatedly high PSA values could prompt unnecessary concern and follow-up.
- False clinical event: an hCG result suggesting miscarriage conflicted with confirmatory evidence of a viable pregnancy.
- Medication-driven error: an anticoagulation-related result led to an unnecessary adjustment before conventional testing showed normal levels.
These examples also explain why a laboratory report should not be treated as self-authenticating. The appropriate response to a result that conflicts with symptoms, previous values or another laboratory is verification, not automatic acceptance or dismissal.
What to do if a past Theranos result conflicts with your health history
People who still have a Theranos report, or who are reviewing medical records from the period when Theranos testing was offered, should discuss the record with the clinician who manages the relevant condition. The following process is practical and does not require assuming that every old result was wrong.
- Identify the exact test and date. Record the analyte, value, units, reference interval, collection date and the location that issued the report.
- Ask which method produced it. The SEC complaint alleged that some testing used traditional or third-party laboratories, so the report’s analyzer or performing-laboratory information matters.
- Compare with contemporaneous evidence. Look for repeat results, hospital records, medication changes, imaging, pregnancy follow-up or other clinical notes that support or contradict the number.
- Repeat clinically important testing through a current laboratory. A clinician can select an appropriate specimen type and validated method. Do not stop or change prescription medication solely because an old result appears inconsistent.
- Document the discrepancy. Keep both reports and ask the clinician to note which result was used for care and why.
- Seek urgent care for urgent symptoms. Chest pain, severe weakness, confusion, heavy bleeding, severe shortness of breath or other emergency symptoms require medical attention regardless of what an old laboratory report says.
This approach separates a record-review question from a medical emergency. It also avoids the opposite mistake of assuming that a conventional result is automatically correct without considering timing, specimen quality and the patient’s condition.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.How to judge claims made by a new blood-testing service
The Theranos experience provides a checklist for evaluating any company that promises many tests from a tiny sample.
Rank #3
- Brand New in box. The product ships with all relevant accessories
Ask what is actually validated
Look for an assay-specific list rather than a promise of “hundreds of tests.” The relevant details are the specimen type, reportable range, precision, accuracy compared with a reference method, interference studies and the populations in which the method was evaluated.
Find out who performs the test
A collection site, a laboratory company and a device manufacturer may be different organizations. Ask for the performing laboratory, the analyzer or method, and the laboratory’s CLIA status. Marketing that emphasizes a proprietary device should not obscure where the patient sample is actually analyzed.
Understand turnaround-time claims
“Fast” can refer to instrument run time rather than the full process from collection to a released, reviewed report. Ask whether the stated time is typical or a best case, whether weekends and transport are included, and how abnormal results are reviewed.
Check the confirmation policy
A responsible service should explain what happens when a result is outside the measuring range, fails quality control or conflicts with a patient’s history. A repeat specimen or a second method is not an admission that all testing is unreliable; it is a normal safeguard for consequential results.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Separate regulatory terms
“CLIA-certified laboratory,” “FDA-cleared device” and “FDA-approved test” are not synonyms. They refer to different parts of the testing system and different kinds of evidence. The exact claim should be matched to the exact assay and intended use.
Common misconceptions about the Theranos comparison
“Every finger-stick test is inaccurate.”
No. Capillary testing can be valid for assays that have been properly designed and validated for capillary specimens. The Theranos record supports concern about the company’s representations and specific assays, not a blanket rejection of capillary collection.
“Every Theranos result was made by the proprietary analyzer.”
No. The government’s case summary and SEC complaint said the company used conventional or third-party machines for some testing while presenting the service as proprietary. The performing method has to be established for the individual report.
“A conventional laboratory result can never be wrong.”
No laboratory method is error-free. Conventional laboratories reduce risk through validated methods, calibration, quality control, documented procedures and the ability to repeat or confirm testing. An unexpected result still deserves clinical review.
Recommended Free Tools
“A tiny sample automatically means a test is better.”
Sample volume is a collection convenience, not a guarantee of analytical quality. Smaller volumes can limit repeat testing and make pre-analytical problems more consequential. Performance must be demonstrated for each assay.
Bottom line: compare validated assays, not marketing stories
Theranos differed from conventional laboratory testing in its promised specimen volume, finger-stick collection model and claim of one proprietary system capable of broad, fast and inexpensive testing. Federal records instead document limited analyzer capability, reliability problems for named analytes, use of conventional machines for some patient testing and clinical examples in which Theranos results conflicted with validated conventional methods.
For patients, the safest lesson is specific rather than sensational: a capillary sample is not automatically bad, and a venous sample is not automatically perfect. Trust a result according to the assay’s validation, the laboratory’s quality system, the method that actually performed the test and whether the number makes sense alongside the patient’s symptoms and other evidence.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
Say something about this film